RIGL
Price
$47.89
Change
-$0.24 (-0.50%)
Updated
Sep 24 closing price
Capitalization
899.06M
46 days until earnings call
Intraday BUY SELL Signals
SRPT
Price
$18.39
Change
-$0.56 (-2.96%)
Updated
Sep 24 closing price
Capitalization
2B
41 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RIGL vs SRPT

RIGL vs SRPT Comparison Chart in %
View a ticker or compare two or three
VS
RIGL vs. SRPT commentary
Sep 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RIGL is a Buy and SRPT is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
RIGL vs SRPT: Fundamental Ratings
RIGL
SRPT
OUTLOOK RATING
1..100
3082
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
84
Overvalued
PROFIT vs RISK RATING
1..100
79100
SMR RATING
1..100
1294
PRICE GROWTH RATING
1..100
3742
P/E GROWTH RATING
1..100
9570
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RIGL's Valuation (45) in the Biotechnology industry is somewhat better than the same rating for SRPT (84). This means that RIGL’s stock grew somewhat faster than SRPT’s over the last 12 months.

RIGL's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as SRPT (100). This means that RIGL’s stock grew similarly to SRPT’s over the last 12 months.

RIGL's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for SRPT (94). This means that RIGL’s stock grew significantly faster than SRPT’s over the last 12 months.

RIGL's Price Growth Rating (37) in the Biotechnology industry is in the same range as SRPT (42). This means that RIGL’s stock grew similarly to SRPT’s over the last 12 months.

SRPT's P/E Growth Rating (70) in the Biotechnology industry is in the same range as RIGL (95). This means that SRPT’s stock grew similarly to RIGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RIGLSRPT
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
74%
MACD
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
83%
Bearish Trend 9 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
86%
COMPARISON
Comparison
Sep 25, 2026
Stock price -- (RIGL: $48.13 vs. SRPT: $18.95)
Brand notoriety: RIGL: Not notable vs. SRPT: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RIGL: 53% vs. SRPT: 131%
Market capitalization -- RIGL: $899.06M vs. SRPT: $2B
RIGL [@Biotechnology] is valued at $899.06M. SRPT’s [@Biotechnology] market capitalization is $2B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.87B. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RIGL’s FA Score shows that 1 FA rating(s) are green while SRPT’s FA Score has 0 green FA rating(s).

  • RIGL’s FA Score: 1 green, 4 red.
  • SRPT’s FA Score: 0 green, 5 red.
According to our system of comparison, RIGL is a better buy in the long-term than SRPT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RIGL’s TA Score shows that 4 TA indicator(s) are bullish while SRPT’s TA Score has 3 bullish TA indicator(s).

  • RIGL’s TA Score: 4 bullish, 4 bearish.
  • SRPT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, RIGL is a better buy in the short-term than SRPT.

Price Growth

RIGL (@Biotechnology) experienced а +8.21% price change this week, while SRPT (@Biotechnology) price change was -4.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.84%. For the same industry, the average monthly price growth was -10.68%, and the average quarterly price growth was +8.45%.

Reported Earning Dates

RIGL is expected to report earnings on Nov 10, 2026.

SRPT is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (-1.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
RIGL
Daily Signal:
Gain/Loss:
SRPT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
YQQQ9.420.09
+0.96%
YieldMax Short N100 Option Income Strategy ETF (YQQQ)
FLAG27.98N/A
N/A
Global X S&P 500 U.S. Market Leaders Top 50 ETF
AGGA24.54-0.14
-0.58%
EA Astoria Beacon Dynamic Core US Fixed Income ETF (AGGA)
VGHY73.02-0.51
-0.70%
Vanguard High-Yield Active ETF (VGHY)
FDLO71.19-0.51
-0.71%
Fidelity Low Volatility Factor ETF (FDLO)